-
ConocoPhillips chief seeks extra US protection of Mideast assets
-
Oil prices jump as Trump's Iran claims raise doubts
-
In world first, antimatter taken on test drive at CERN
-
New Chile president withdraws support for Bachelet UN chief bid
-
Mammals cannot be cloned infinitely, mice study discovers
-
600-year-old pinot noir grape found in medieval French toilet
-
NASA to build $20 bn moon base, pause orbital lunar station plans
-
Czech 'arks' help preserve Ukraine's cultural heritage
-
Shiffrin closes on World Cup overall title with slalom win
-
Griezmann to leave Atletico for Orlando at end of season
-
New Nice mayor poses a 'real problem' for 2030 Winter Olympics
-
Afghanistan announces release of detained US citizen
-
Meta awaits verdict in New Mexico child safety trial
-
Pinheiro Braathen wins World Cup giant slalom title after Odermatt crashes
-
Aid flotilla arrives in Cuba as US oil blockade bites
-
Residents recount guilt, chaos in hearing on deadly Hong Kong fire
-
Oil prices jump, stocks slip as Trump's Iran claims raise doubts
-
World Snooker Championship to stay at Crucible
-
Mercedes new electric VLE: Price and performance?
-
Outlook worsens for whale stranded on German coast
-
Xiaomi quarterly profit slumps despite annual EV gains
-
Iran, Israel trade strikes despite Trump talk of negotiations
-
IPL's Bengaluru to keep 11 seats empty in honour of stampede dead
-
Oil prices jump, stocks waver after Trump's Iran claim
-
'A top person': Who is the US dealing with in Iran?
-
In Lebanon's Tyre, ancient site threatened by Israeli bombs
-
US-Israeli war on Iran is 'breach of international law': German president
-
Iran strikes Israel, denies Trump talks
-
Mbappe says injury is behind him, all systems go for World Cup
-
Supporters' group file lawsuit against 'excessive' World Cup ticket prices
-
Gas shortages push India's poor back to wood and coal
-
'Plundered': Senegal fishers feel sting of illegal, industrial vessels
-
Iran hits Israel with missiles after denying Trump talks
-
Stocks rise on Trump U-turn but unease sees oil bounce
-
Trans community alarmed as India moves to curb LGBTQ rights
-
Families' nightmare fight for justice in Austria child sex cases
-
Tiger Woods to return to action in TGL with Masters looming
-
Australia, EU agree sweeping new trade pact eight years in the works
-
Back to black: facing energy shock, Asia turns to coal
-
Iran fires new wave of missiles at Israel after denying Trump talks
-
Manila's jeepney drivers struggle as Mideast war sends diesel cost soaring
-
The contenders vying to be next Danish leader
-
India's historic haveli homes caught between revival and ruin
-
Denmark votes in close election, outgoing PM tipped to win
-
N. Korea's Kim vows 'irreversible' nuclear status, warns Seoul of 'merciless' response
-
Pressure on Italy as play-off hopefuls eye 2026 World Cup
-
Malinin and Sakamoto seek solace at figure skating worlds as Olympic champions absent
-
'Perfect Japan' posts spark Gen Z social media backlash
-
Asian stocks rise on Trump U-turn but unease sees oil bounce
-
Pistons halt Lakers streak while Spurs, Thunder win
US panel recommends nonprescription use of contraception pill
A US panel of health experts voted Wednesday in favor of making birth control pills available without a prescription, a move backed by reproductive rights advocates especially in the wake of a Supreme Court ruling overturning the national right to abortion.
The independent panel voted unanimously that the benefits of allowing the medicine, Opill, to be sold over the counter, outweighed the risks and would reduce hurdles associated with visiting a doctor that impact lower income groups disproportionately.
"I believe that the efficacy and safety of this birth control form was established over half a century ago," said panelist Jolie Haun of the James A. Haley Veterans' Hospital.
"We now have been presented with ample data demonstrating the effective safe use and benefits for people who want to have access to reproductive autonomy."
The committee's votes are usually accepted by the Food and Drug Administration, which means the pill, which is made by HRA Pharma, might be available without prescription in the coming weeks.
While likely, approval is not assured. FDA scientists highlighted safety concerns, such as the potential impact on people with a history or current diagnosis of breast cancer, or whether they would understand the pill needs to be taken the same time every day to prevent pregnancy.
"There is also concern that some consumers may not consistently use the product correctly on a chronic basis and be at risk for pregnancy, but not recognize that they are pregnant because of the irregular bleeding that would be ascribed to the known side effect," the FDA wrote in a document.
The push for a non-prescription pill has taken on new urgency in light of a Supreme Court decision overturning the constitutional right to abortion, leading to numerous bans and severe restrictions in conservative states.
It has received support from health groups such as the American Medical Association and American College of Obstetricians and Gynecologists.
If the pill is approved, the US would join more than 100 other countries where the pill is available without a prescription, including the UK which requires a consultation with a pharmacist.
Opill is known as a "mini pill" because it contains progestin only.
Another company, Cadence, is in talks with the FDA about making its combination pill, which contains both estrogen and progestin, available over the counter.
J.AbuShaban--SF-PST